PRF Technologies Ltd.

PRFX

IL0011651580

Pharmaceuticals

Market Closed - Nasdaq 16:00:00 2026-11-03 EST			5-day change	1st Jan Change
0.7110 ^USD	-5.20%		-6.29%	-77.84%

11-03	S.H.N. Files Lawsuit to Compel PRF Technologies to Convene Special General Meeting	CI
09-24	Shamir Capital Seeks Board Changes at PRF Technologies	CI

Top Premarket Decliners

Published on 06/16/2026 at 07:34 am EDT

MT Newswires

This article is reserved for our members.

Continue with Google Continue with Apple Continue with LinkedIn

or by email

Continue with an email.

Latest news about PRF Technologies Ltd.

11-03	S.H.N. Files Lawsuit to Compel PRF Technologies to Convene Special General Meeting	CI
09-24	Shamir Capital Seeks Board Changes at PRF Technologies	CI
09-16	PRF Technologies Ltd. Announces GridFeed To Explore Strategic Growth Opportunity In AI Data Center Power Optimization	CI
09-09	PRF Technologies Establishes GridFeed As Standalone Subsidiary To Pursue Strategic Alliances For AI-Driven Renewable Energy Trading Platform	CI
09-03	PRF Technologies Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
07-15	Prf Technologies Expands Deepsolar Predict Platform with Battery-To-Revenue Intelligence	CI
07-08	PRF Technologies DeepSolar Business Unit Completes Initial Validation Phase For DeepSolar Predict AI-Driven Revenue Optimization Platform	CI
06-25	PRF Technologies Says PRF-110 Showed Comparable Efficacy to Zynrelef in Preclinical Study	MT
06-25	PRF Technologies Reports Expanded Preclinical Results For PRF-110 In Head-To-Head Comparison With Approved Benchmark	CI
06-16	Top Premarket Decliners	MT
05-29	Top Premarket Gainers	MT
05-28	PRF Technologies Ltd. Advances DeepSolar Predict Toward Commercial Launch As AI Platform Targets Revenue Optimization Across Renewable Energy Markets	CI
05-26	PRF Technologies Reports Positive Preclinical Results for PRF-110 in Head-To-Head Study with ZYNRELEF	CI
04-28	PRF Technologies Ltd. Announces FDA Clearance Of IND Application For OcuRing-K Phase II Clinical Trial	CI
04-06	Top Premarket Gainers	MT

PRF Technologies Ltd is an Israel-based company engaged primarily in pharmaceutical sector. The Company is a producer of speciality pharmaceuticals as well as energy analytics powered by artificial intelligence (AI). The Firm develops reformulated and sustainedâ€‘release drugâ€‘delivery platforms that combine proven generic medicines with proprietary extendedâ€‘release systems to improve patient outcomes. One of the Company's products is PRFâ€‘110 - a ropivacaineâ€‘based formulation designed to deliver localised, extended postoperative analgesia. The Company also advances OcuRingTD, a bioâ€‘erodible drugâ€‘release ring integrated with intraocular lenses for continuous delivery of medications in cataract surgery.In the energy analytics sector the Company operates DeepSolar platform that provides AIâ€‘powered monitoring, forecasting, and optimisation tools for solar asset performance.

Employees

Sector

Pharmaceuticals

More about the company